Cefepime: Difference between revisions
imported>David E. Volk m (→External links) |
imported>David E. Volk mNo edit summary |
||
Line 16: | Line 16: | ||
'''Cefepime''' is a fourth-generation [[cephalosporin]] [[antibiotic]] that was developed in 1994. It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe [[nococomial]] [[pneumonia]], infections of a multi-resistant bacterial strain and the treatment of [[febrile]] [[neutropenia]]. It is indicated for the treatment of pneumonia caused by [[Streptococcus pneumoniae]], [[Pseudomonas aeruginosa]], [[Klebsiella pneumoniae]], or [[Enterobacter]] species and also for empiric treatment of febrile neutropenic patients and urinary tract infections caused by [[Escherichia coli]] or [[Klebsiella pneumoniae]] for severe infections, or, when concurrent [[bacteremia]] is present, for milder infections of Escherichia coli, Klebsiella pneumoniae, or [[Proteus mirabilis]]. It is also used to treat skin and skin structure infections caused by methicillin-resistant strains of Staphylococcus aureus and Streptococcus pyogenes. It also used in combination with [[metronidazole]] for complicated intra-abdominal infections caused by caused by many bacteria. | '''Cefepime''' is a fourth-generation [[cephalosporin]] [[antibiotic]] that was developed in 1994. It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe [[nococomial]] [[pneumonia]], infections of a multi-resistant bacterial strain and the treatment of [[febrile]] [[neutropenia]]. It is indicated for the treatment of pneumonia caused by [[Streptococcus pneumoniae]], [[Pseudomonas aeruginosa]], [[Klebsiella pneumoniae]], or [[Enterobacter]] species and also for empiric treatment of febrile neutropenic patients and urinary tract infections caused by [[Escherichia coli]] or [[Klebsiella pneumoniae]] for severe infections, or, when concurrent [[bacteremia]] is present, for milder infections of Escherichia coli, Klebsiella pneumoniae, or [[Proteus mirabilis]]. It is also used to treat skin and skin structure infections caused by methicillin-resistant strains of Staphylococcus aureus and Streptococcus pyogenes. It also used in combination with [[metronidazole]] for complicated intra-abdominal infections caused by caused by many bacteria. | ||
Revision as of 16:31, 5 April 2009
| |||||||
cefepime | |||||||
| |||||||
Uses: | antibiotic drug | ||||||
Properties: | beta-lactam | ||||||
Hazards: | see drug interactions | ||||||
|
Cefepime is a fourth-generation cephalosporin antibiotic that was developed in 1994. It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe nococomial pneumonia, infections of a multi-resistant bacterial strain and the treatment of febrile neutropenia. It is indicated for the treatment of pneumonia caused by Streptococcus pneumoniae, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species and also for empiric treatment of febrile neutropenic patients and urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae for severe infections, or, when concurrent bacteremia is present, for milder infections of Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. It is also used to treat skin and skin structure infections caused by methicillin-resistant strains of Staphylococcus aureus and Streptococcus pyogenes. It also used in combination with metronidazole for complicated intra-abdominal infections caused by caused by many bacteria.